Skip to main content
INDVIndivior Pharmaceuticals, Inc.Hold6.0·$35.17+0.98%

Indivior Pharmaceuticals (INDV) Q2 2026 earnings — TrendMatrix coverage

BEAT+24.8% vs estimateEPS $1.15 vs $0.92 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$1.15
Estimate
$0.92
Surprise
+24.8%
Revenue (period 2026-06-30)
$343.0M
Score at report (before → after)
6.86.9/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Indivior Pharmaceuticals (INDV) beat the $0.92 estimate with diluted EPS of $1.15 — a large 24.8% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.8/10) to Hold at 6.9/10 after the report.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates INDV Hold at 6.0/10.

4 of the last 4 quarters beat the estimate; this quarter's +24.8% surprise compares with a +41.7% four-quarter average. Next scheduled report: 2026-11-05.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Strong earnings beat streak (4/4)

What argues against it

  • Negative momentum
  • Momentum score 1.4/10 — below 4.5 minimum

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$35.17
Price target
$41.65
Stop
$33.30
Upside to target
+18.4%
Reward-to-risk
3.1:1

The stock trades at 12.6× trailing but 7.1× forward earnings — consensus estimates already build in a substantial earnings recovery.

Risk check: RSI 19 — a level conventionally read as oversold.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

INDV at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Drug Manufacturers - Specialty & Generic
Market cap
$4.11B
P/E (fwd)
7.1
P/E (ttm)
12.6
52-week range
$22.22$42.81
Off 52-week high
17.8%
RSI (14)
19
Volume vs avg
0.26×
Score today
6.0/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks INDV Earnings Q2 2026 earnings